Invention Grant
- Patent Title: P300/CBP HAT inhibitors
-
Application No.: US16970169Application Date: 2019-02-15
-
Publication No.: US11274090B2Publication Date: 2022-03-15
- Inventor: Jonathan E. Wilson , Francois Brucelle , Julian R. Levell
- Applicant: Constellation Pharmaceuticals, Inc.
- Applicant Address: US MA Cambridge
- Assignee: Constellation Pharmaceuticals, Inc.
- Current Assignee: Constellation Pharmaceuticals, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: McCarter & English, LLP
- Agent Steven G. Davis; Michael J. DeGrazia
- International Application: PCT/US2019/018158 WO 20190215
- International Announcement: WO2019/161162 WO 20190822
- Main IPC: C07D401/04
- IPC: C07D401/04 ; C07D209/08 ; C07D213/75 ; C07D215/08 ; C07D231/12 ; C07D231/40 ; C07D237/08 ; C07D295/135 ; C07D401/14 ; C07D403/04 ; C07D405/04 ; C07D413/04 ; C07D417/04 ; C07D487/04 ; C07D491/107
Abstract:
Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).
Public/Granted literature
- US20210115008A1 P300/CBP HAT INHIBITORS Public/Granted day:2021-04-22
Information query
